AmpliPhi Biosciences to Combine With Special Phage Services to Create World's Leading Anti-Infective Company Focused on Bacteriophage-Based Therapies

RICHMOND, Va. & LONDON & SYDNEY--(BUSINESS WIRE)--AmpliPhi Biosciences Corporation [APHB.PK] (“Ampliphi”), today announced that it has offered to acquire Brookvale, Sydney-based Special Phage Services (“SPS”). The combination of the two companies would result in the creation of a leading anti-infective company focused on developing phage-based therapies to combat the growing threat of antibiotic-resistant infection.